Skip to main content
SpringerLink
Log in

Serum levels of selected chemokines in systemic lupus erythematosus patients

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Chemokines promote leukocyte traffic into the site of inflammation. Serum levels of monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), interferon-gamma-inducible protein 10 (IP-10), and interleukin-8 (IL-8) were evaluated in 48 treated women with systemic lupus erythematosus (SLE) and mild-to-moderate disease severity. The results were compared between the whole SLE group and the control (29 women). The relationships between chemokines, their concentrations, and peripheral blood leukocyte count and between the chemokines and individual leukocyte populations (polymorphonuclear leukocytes—PMNs, lymphocytes—Ls, monocytes—Ms, eosinophils) counts were determined. The relationships between the analyzed chemokines were also determined in the control. SLE subjects had significantly higher MCP-1, SDF-1, IP-10, and lower IL-8 concentrations compared to the control. Moderate, positive correlations between MCP-1/SDF-1, SDF-1/IP-10 and a negative correlation between MCP-1/IL8 were observed in the patient group. Moderate, negative correlations were found between SDF-1/total leukocyte count, SDF-1/absolute number of PMNs as well as between IP-10/total leukocyte count, IP-10/absolute PMNs, Ls, and Ms counts in peripheral blood of SLE group. We suggest that the obtained results and correlations observed between the examined parameters might be used to monitor SLE course and progression. However, further randomized clinical studies should be carried out on in untreated and treated patients with SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kong KO, Tan AW, Thong BYH, Lian TY, Cheng YK, Teh CL, Koh ET, Chng HH, Lau TC, Leong KR, Leung BP, Howe HS (2009) Enhanced expression of interferon-inducible protein -10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 156:134–140

    Article  PubMed  CAS  Google Scholar 

  2. Hrycek A, Pochopień-Kenig G, Ścieszka J (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40:217–222

    Article  PubMed  CAS  Google Scholar 

  3. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Tekehara K, Sato S (2003) Serum concentrations of the CXC chemokines Interleukin 8 and Growth-Regulated Oncogene-α are elevated in patients with systemic sclerosis. J Rheumatol 30:1524–1528

    PubMed  CAS  Google Scholar 

  4. Kaneko H, Ogasawara H, Naito T, Akimoto H, Hishikawa T, Lee S, Segikawa I, Tokano Y, Takasaki Y, Hirose S-I, Hashimoto H (1999) Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26:568–573

    PubMed  CAS  Google Scholar 

  5. Wang A, Guilpain Ph, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst AM, Boudreaux Ch, Roux Ch, Wakeland EK, Davis LS, Batteux F, Mohan Ch (2010) Dysregulated expression of CXCR4/CXCL12 in subset of patients with systemic lupus erythematosus. Arthritis Rheum 62:3436–3446

    Article  PubMed  Google Scholar 

  6. Chong BF, Mohan Ch (2009) Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 13:1147–1153

    Article  PubMed  CAS  Google Scholar 

  7. Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Hung F, Zhang XJ (2005) The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res 296:366–371

    Article  PubMed  CAS  Google Scholar 

  8. Alzawawy A, Zohary M, Ablordiny M, Eldalie M (2009) Estimation on monocyte-chemoattractant protein-1 (Mcp-1) level in patients with lupus nephritis. Intern J Rheum Dis 12:311–318

    Article  Google Scholar 

  9. Lima G, Soto-Vega E, Atisha-Fregoso Y, Sánchez-Guerrero J, Vallejo M, Vargas-Alarcón G, Liorente L (2007) MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Human Immunol 68:980–985

    Article  CAS  Google Scholar 

  10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  11. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  12. Suzuki M, Hashizume M, Yoshida H, Mihara M (2010) Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30:309–315

    Article  PubMed  CAS  Google Scholar 

  13. Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, von Feldt JM (2007) Monocyte chemoattractant protein-1: plasma concentration and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746

    PubMed  CAS  Google Scholar 

  14. Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209–215

    Article  PubMed  CAS  Google Scholar 

  15. Bauer JW, Petri M, Batliwalla FM, Koeuth Th, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098–3107

    Article  PubMed  CAS  Google Scholar 

  16. Robak E, Kulczycka L, Sysa-Jędrzejowska A, Wierzbowska A, Robak T (2007) Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 18:9–15

    Google Scholar 

  17. Narumi S, Takeuchi T, Kobayashi Y, Konishi K (2000) Serum levels of IFN- inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:1561–1565

    Article  PubMed  CAS  Google Scholar 

  18. Szekanecz Z, Szücs G, Szántó S, Koch AE (2006) Chemokines in rheumatic diseases. Curr Drug Targets 7:91–102

    Article  PubMed  CAS  Google Scholar 

  19. Hsich S-C, Wu T-H, Tsai C-Y, Li K-J, Lu M-C, Wu C-H, Yu C-L (2008) Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology 47:150–157

    Article  Google Scholar 

  20. Link DC (2005) Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 32:169–178

    Article  PubMed  CAS  Google Scholar 

  21. Klebanoff SJ, Clark BA (1978) The neutrophil: function and clinical disorders. North-Holland, Amsterdam

    Google Scholar 

  22. Matamoros MC, Walker BK, Van Dyke K, Van Dyke CJ (1983) Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacology 27:29–39

    Article  PubMed  CAS  Google Scholar 

  23. Kotulová D, Stefanovic J (1983) Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone. J Hyg Epidemiol Microbiol Immunol 27:253–257

    PubMed  Google Scholar 

  24. Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J, Barbosa P, Mendenca T, Vasconcelos C (2009) Linfopenia T CD4 no lúpus eritematoso sistémico. Acta Rheumatol Port 34:200–206

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Student Scientific Section at the Department of Internal, Autoimmune, and Metabolic Diseases, Medical University of Silesia, ul. Medyków 14, 40-752, Katowice, Poland

    Eugeniusz Hrycek

  2. Department of Medical Biophysics, Medical University of Silesia, ul. Medyków 14, 40-752, Katowice, Poland

    Andrzej Franek & Edward Błaszczak

  3. Department of Internal, Autoimmune, and Metabolic Diseases, Medical University of Silesia, ul. Medyków 14, 40-752, Katowice, Poland

    Justyna Dworak & Antoni Hrycek

Authors
  1. Eugeniusz Hrycek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrzej Franek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Błaszczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Justyna Dworak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antoni Hrycek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoni Hrycek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hrycek, E., Franek, A., Błaszczak, E. et al. Serum levels of selected chemokines in systemic lupus erythematosus patients. Rheumatol Int 33, 2423–2427 (2013). https://doi.org/10.1007/s00296-012-2393-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2393-5

Keywords

Search

Navigation